Alpers Syndrome
A severe inherited mitochondrial disorder caused by POLG gene mutations, characterized by progressive seizures, developmental regression, and liver disease, typically presenting in early childhood.
- Genetic testing confirmatory
- Seizure and liver monitoring
- Specialist coordination available
- Inheritance Pattern
- Autosomal Recessive
- Gene Involved
- POLG
- Typical Onset
- Ages 2โ4 Years
- Care Focus
- Seizure & Liver Management
Condition Overview
Alpers Syndrome, also known as Alpers-Huttenlocher Syndrome, is a severe inherited mitochondrial disorder caused by mutations in the POLG gene, which encodes the enzyme responsible for replicating mitochondrial DNA. Loss of this function leads to progressive mitochondrial DNA depletion, primarily affecting the brain and liver.
The condition typically presents in early childhood, often after a period of normal development, with a triad of refractory seizures, progressive neurological regression, and liver disease. Illness or certain medications can sometimes trigger rapid deterioration, making careful medical management especially important.
Because Alpers Syndrome affects both the brain and liver simultaneously, coordinated neurology and hepatology care is essential from the time of diagnosis.
Types and Subtypes
Alpers Syndrome is generally considered a single clinical entity within the broader group of POLG-related mitochondrial disorders, though age of onset and rate of progression can vary.
Symptoms and Signs
Alpers Syndrome often presents after a period of apparently normal development, with symptoms emerging and progressing over weeks to months.
Causes and Risk Factors
Alpers Syndrome is caused entirely by inherited POLG gene mutations; it is not caused by anything during pregnancy or after birth, though certain medications can trigger acute deterioration.
Diagnosis and Investigations
Diagnosis combines clinical findings with neurological, hepatic, and genetic evaluation.
Disease Severity Stratification
Alpers Syndrome is not staged like cancer; clinical course is generally classified by the degree of seizure control and organ involvement.
Standard Treatment Options
There is no cure for Alpers Syndrome; treatment focuses on seizure control, liver monitoring, and supportive care while carefully avoiding medications that can worsen liver function.
Advanced & Emerging Therapies
There is currently no disease-modifying therapy for Alpers Syndrome; research is focused on mitochondrial-targeted approaches.
Investigational
Mitochondrial-targeted antioxidant research
Early research is exploring whether mitochondrial-targeted compounds could reduce cellular stress in POLG-related disease.
Precision Medicine
Genotype-informed seizure and liver management
Care plans are increasingly informed by the confirmed POLG genotype to avoid medications with elevated hepatotoxicity risk.
Gene Therapy
Gene- and mitochondria-targeted research approaches
Preclinical research into correcting mitochondrial DNA depletion is ongoing but not yet clinically available for Alpers Syndrome.
Biomarkers & Precision Medicine
Genetic and biochemical markers guide diagnosis, medication safety, and disease monitoring.
When a Second Opinion May Be Important
Given the complexity of Alpers Syndrome and the risk of medication-related complications, specialist input is particularly valuable.
Clinical Trials & Research
Prognosis & Outcome Factors
Alpers Syndrome is a progressive condition, and prognosis depends substantially on seizure control, liver involvement, and avoidance of hepatotoxic medications.
Supportive Care and Living With Alpers Syndrome
Ongoing multidisciplinary support helps families manage the progressive neurological and hepatic effects of Alpers Syndrome.
How CancerFax Helps You Explore Treatment Options
CancerFax can help review genetic and neurology reports, coordinate a specialist second opinion, and connect families with mitochondrial disease centers experienced in managing Alpers Syndrome.
Get a free case reviewFrequently Asked Questions
Alpers Syndrome, also known as Alpers-Huttenlocher Syndrome, is a severe inherited mitochondrial disorder caused by POLG gene mutations, leading to progressive seizures, neurological regression, and liver disease.
Children often appear to develop normally before experiencing refractory seizures, loss of developmental milestones, and signs of liver dysfunction, typically between ages 2 and 4.
Alpers Syndrome is caused by inherited mutations in the POLG gene, which impair mitochondrial DNA replication.
Diagnosis combines clinical history, EEG and MRI findings, liver function testing, and confirmatory POLG genetic testing.
Valproate and related medications can trigger acute, severe liver failure in children with POLG mutations and are generally avoided once the diagnosis is known or suspected.
There is currently no cure. Care focuses on seizure management, liver monitoring, and supportive treatment.
Yes, it is inherited in an autosomal recessive pattern, meaning both parents must carry a mutated POLG gene copy.
Care typically involves neurology, hepatology, genetics, and palliative care specialists.
Yes, genetic counseling is recommended to clarify recurrence risk and support family planning decisions.
Yes. CancerFax can help review medical and genetic reports, coordinate a second opinion, and connect families with mitochondrial disease specialist centers experienced in managing Alpers Syndrome.
Have an Alpers Syndrome Diagnosis to Review?
Share your child's reports with CancerFax to explore specialist second opinions and coordinated supportive care.